Table 3. Prognosis accuracy of interim and end-of-treatment PET/CT interpreted using different therapeutic evaluation criteria.

	Sensitivity	Specificity	PPV	NPV	Accuracy
iPET4 (n = 181)
PFS
rDS	44.28%	93.69%	81.58%	72.72%	74.58%
ΔSUVmax	41.43%	94.59%	82.85%	71.92%	74.03%
Deauville Score	57.14%	82.88%	67.79%	75.41%	72.93%
ΔSUVmax + rDS	41.43%	92.79%	78.38%	71.53%	72.93%
Menton 2011 criteria	45.71%	92.79%	80.00%	73.05%	74.58%
OS
rDS	43.63%	88.89%	63.16%	78.32%	75.14%
ΔSUVmax	40.00%	89.68%	62.85%	77.39%	74.58%
Deauville Score	56.36%	77.78%	52.54%	80.32%	71.27%
ΔSUVmax + rDS	40.00%	88.09%	59.46%	77.08%	73.48%
Menton 2011 criteria	45.45%	88.09%	62.50%	78.72%	75.14%
PET-eot (n = 165)
PFS
rDS	51.61%	98.06%	94.12%	77.10%	80.60%
Deauville Score	58.06%	88.35%	75.00%	77.77%	76.96%
OS
rDS	55.32%	93.22%	76.47%	83.97%	82.42%
Deauville Score	61.70%	83.90%	60.42%	84.61%	77.57%

PPV: positive predictive value; NPV: negative predictive value; PFS: progression-free survival

OS: overall survival.

rDS: ratio Deauville Score = Tumour/Liver SUVmax ratio >1.4 as positive for iPET4 and PET-eot

Deauville Score: score≥ 4 as positive for iPET4 and PET-eot; ΔSUVmax: ≤ 70% as positive for iPET4

ΔSUVmax + rDS: ΔSUVmax if eligible patient and rDS if SUVmax initial tumour <10 and / or if SUVmax residual tumour >5.

Menton 2011 criteria: ΔSUVmax if eligible patient and DS if SUVmax initial tumour <10 and / or if SUVmax residual tumour >5.